Genentech reports detailed data for Tecentriq in first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported detailed data from the Phase III IMpower150 trial of Tecentriq atezolizumab (MPDL3280A, RG7446) as first-line treatment of advanced stage IV non-squamous non-small cell lung cancer (NSCLC), including results from a subgroup of patients with a T effector (Teff) gene signature expression biomarker. Teff measures mRNA expression of PD-L1, chemokine

Read the full 585 word article

User Sign In